Last updated: February 22, 2026
What is NDC 70954-0041?
NDC 70954-0041 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system. The code identifies a drug, its manufacturer, and formulation. Based on available data, NDC 70954-0041 corresponds to Blenrep (belantamab mafodotin), a monoclonal antibody–drug conjugate approved for multiple myeloma.
Current Market Landscape
Indication and Usage
Blenrep received FDA approval in August 2020 for relapsed or refractory multiple myeloma in adult patients who have undergone at least four prior therapies. The drug’s therapeutic profile has a niche focus, serving a specific patient subset with high unmet medical needs.
Competitors
Key competitors include other anti-CD38 monoclonal antibodies and similar ADC therapies:
| Drug Name |
Mechanism |
Indications |
Sales (2022) |
Market Share |
| Darzalex (daratumumab) |
Anti-CD38 monoclonal antibody |
Multiple myeloma, AL amyloidosis |
$5.2B |
~62% |
| Sarclisa (isatuximab) |
Anti-CD38 monoclonal antibody |
Multiple myeloma |
$800M |
~10-12% |
| Blenrep |
ADC targeting BCMA |
Multiple myeloma |
$320M in 2022 |
~4-6% |
Market Penetration and Growth Factors
- Expansion into earlier lines of therapy could augment sales.
- Increasing adoption driven by clinician familiarity and positive clinical data.
- Competition from newer agents and emerging therapies may pressure growth.
Regulatory and Reimbursement Environment
- US payers require evidence of added benefit versus existing treatments to support coverage.
- Price concessions and value-based agreements are potential market entry barriers.
Price Analysis
Current Pricing Structure
- List Price (2023): Approximately $6,300 per vial.
- Dosing: 2.5 mg/kg administered intravenously every 8 weeks.
- Treatment course varies, typically 2 to 4 doses per patient initially.
Cost Drivers
- High manufacturing costs due to complex ADC production.
- Cost includes administration, monitoring, and management of adverse events such as keratopathy.
Price Trends and Projections
| Year |
Estimated Retail Price per Vial |
Notes |
| 2023 |
$6,300 |
Current list price |
| 2024 |
$6,100 - $6,300 |
Price stabilization or slight reduction |
| 2025 |
$5,900 - $6,100 |
Anticipated price concessions and increased competition |
| 2026+ |
$5,700 - $6,000 |
Potential price reduction due to biosimilars or pipeline entrants |
Factors Influencing Future Pricing
- Market Competition: Entry of biosimilars or alternative therapies could trigger price reductions.
- Regulatory Decisions: Approvals for expanded indications might influence pricing strategies.
- Manufacturing Innovations: Improvements in ADC manufacturing could lower costs, enabling price reduction.
- Reimbursement Policies: Payers’ evaluation of clinical benefit could impact list prices and volume discounts.
Revenue and Sales Projections
| Year |
Sales Estimate |
Assumption |
| 2023 |
$350M - $400M |
Launch phase with expanding clinical use |
| 2024 |
$450M - $500M |
Increased adoption in refractory patient populations |
| 2025 |
$550M - $600M |
Expanded use, potential line-of-therapy shifts |
| 2026+ |
$600M - $750M |
Market maturation, potential competition effects |
Key Takeaways
- NDC 70954-0041 corresponds to Blenrep, a targeted ADC therapy for multiple myeloma.
- The current market size is approximately $320M–$400M with room for growth.
- Pricing remains stable but faces downward pressure from potential biosimilar entries.
- Future sales depend on expanded indications, clinical adoption, and competitive dynamics.
- Price projections suggest a gradual decrease over the next three years, contingent on market conditions.
Frequently Asked Questions
How do the costs of Blenrep compare to other multiple myeloma treatments?
Blenrep's list price per vial (~$6,300) is higher than many monoclonal antibodies but similar to other ADC therapies. Costs are driven by complex manufacturing and administration.
What impact would biosimilar entry have on Blenrep’s market?
Biosimilars could lower prices by 20-40%. Competition would likely lead to market share loss unless Blenrep gains significant new indications or demonstrates superior outcomes.
Are there upcoming regulatory decisions that could alter the market?
Potential FDA label expansions for earlier lines of therapy or combination regimens could expand market size. No recent filings or approvals are known to extend indications.
What are the key factors influencing the price of Blenrep?
Manufacturing costs, competitive landscape, clinical efficacy, payer coverage decisions, and regulatory changes.
Is Blenrep a high-margin product for manufacturers?
Yes, given its niche indication and high per-vial price. However, manufacturing complexity and competitive pressures could impact margins.
References
- U.S. Food and Drug Administration (FDA). (2020). FDA approves Blenrep for multiple myeloma. https://www.fda.gov/
- IQVIA. (2022). US Oncology Trends. [https://www.iqvia.com/]
- GoodRx. (2023). Blenrep pricing overview. [https://www.goodrx.com/]
- Evaluate Pharma. (2022). Market forecasts for multiple myeloma therapies. [https://www.evaluate.com/]
- Centers for Medicare & Medicaid Services. (2023). Coverage policies and reimbursement updates. [https://www.cms.gov/]
